The role of PD-L1 in thyroid malignancies has been studied; however, the role of CTLA-4 needs to be explored [7-9]. Most of the studies on PD‐L1 expression in various follicular cell-derived thyroid carcinomas have used TPS and CPS with a cut-off of 1% and 5%; only Cantara et al. used a cut-off of 25% of TPS to assess PD-L1 immunoexpression in ATC [13]. The gene discussed is CTLA4; the disease is thyroid gland carcinoma.